| Symbol | ALC |
|---|
| Name | ALCON INC |
|---|
| Sector | HEALTH CARE |
|---|
| Region | UNDEFINED |
|---|
| Industry | Ophthalmic Goods |
|---|
| Address | 6201 SOUTH FREEWAY, FORT WORTH, TX 76134 |
|---|
| Telephone | 817 293 0450 |
|---|
| Fax | — |
|---|
| Email | — |
|---|
| Website | — |
|---|
| Incorporation | UNDEFINED |
|---|
| Incorporated On | — |
|---|
| Employees | — |
|---|
| Fiscal Year | — |
|---|
| Public Since | — |
|---|
| Exchanges | NASDAQ |
|---|
| Auditor | — |
|---|
| Audit Status | NOT PROVIDED |
|---|
| Reporting Status | — |
|---|
| CIK | — |
|---|
| Description | Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Additional info from NASDAQ:
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |
|---|
2026-04-06 12:03
Alcon - Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and
Toric IOLs, at ASCRS 2026
Read more
2026-04-06 12:03
Alcon Launches Clareon TruPlus, Enhanced Design Monofocal and Toric IOLs, at ASCRS 2026
Read more
2026-04-02 20:34
ALCON INC (ALC) Files Form 6-K
Read more
2026-04-02 20:30
Alcon - Alcon Publishes Agenda for 2026 Annual General Meeting
Read more
2026-04-02 20:30
Alcon Publishes Agenda for 2026 Annual General Meeting
Read more
2026-04-02 20:30
Alcon Publishes Agenda for 2026 Annual General Meeting
Read more
2026-03-19 11:00
Algoma Central Corporation Announces Renewal of Normal Course Issuer Bid
Read more
2026-03-16 20:57
Alcon - Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
Read more
2026-03-16 20:57
Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement
Read more
2026-03-05 12:00
Algoma Central Corporation Reports Financial Results for Fiscal 2025
Read more
No clinical trials found for this company.
No clinical products found for this company.